Annual Report for Cline Scientific AB (publ), 556867-8238, for the period 1 January – 31 December 2022

Cline Scientific AB (publ) ("Cline" or the "Company") issues the following annual report for 2022.

The report is published at www.clinescientific.com/financial-reports

The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 8:30 CET on 29 March 2023.

For more information, please contact:

Patrik Sundh, CEO

Email: patrik.sundh@clinescientific.com

Phone: +46 703-585 088

About Cline Scientific

Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.
 

Cline Scientific AB (publ) Phone: 031-387 55 55

Argongatan 2C Email: info@clinescientific.com

431 53 MÖLNDAL  Website: www.clinescientific.com